



PATENT  
Attorney Docket No.: MEDIV2010-4

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Epstein et al. Art Unit: 1636  
Application No.: 10/618,183 Examiner: R. Akhavan  
Filing Date: July 10, 2003 Confirmation No.: 4304  
Title: INJECTION OF BONE MARROW-DERIVED CELLS AND MEDIUM  
FOR ANGIOGENESIS

MAIL STOP AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:


In accordance with 37 C.F.R. § 1.97, Applicants bring the reference listed on the attached Form PTO-1449 to the attention of the Examiner for the above-identified application. A copy of the reference will be found in prior application, U.S. Serial No. 10/160,514, filed May 30, 2002, which is relied upon for an earlier filing date under 35 U.S.C. § 120.

It is respectfully requested that the reference be considered in the examination of this application and its consideration be made of written record in the application file.

09/24/2004 DENMANU1 00000004 10618183

02 FC:1806

180.00 OP

CERTIFICATION UNDER 37 CFR §1.8	
I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service with sufficient postage as first class mail on this date, <b>September 20, 2004</b> , in an envelope addressed to: MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Gregory P. Austin (Name of Person Mailing Paper)	
 (Signature)	September 20, 2004 (Date)


In re Application of:  
Epstein et al.  
Application No.: 10/618,183  
Filed: July 10, 2003  
Page 2

PATENT  
Attorney Docket No.: MEDIV2010-4


Enclosed is Check No. 566699 in the amount of \$235.00 in payment of the Terminal Disclaimer fee (\$55.00) and the Information Disclosure Statement submission fee (\$180.00). The Commissioner is hereby authorized to charge any other fees that may be associated with this communication, or credit any overpayment, to Deposit Account No. 50-1355.

Respectfully submitted,

Date: September 20, 2004

  
June M. Learn, J.D., Ph.D.  
Registration No. 31,238  
Telephone: (858) 677-1416  
Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP  
4365 Executive Drive, Suite 1100  
San Diego, California 92121-2133  
USPTO CUSTOMER NO. 28213

<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office 	Docket No.: MEDIV2010-4	Application No.: 10/618,183
	Applicants: Epstein et al.	Confirmation No.: 4304
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Filing Date: July 10, 2003	Group Art Unit: 1636

### U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

### FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	AA	Desgranges et al., "Beneficial use of fibroblast growth factor 2 and RGTA, a new family of heparan mimics, for endothelialization of PET prostheses", <i>J Biomed Mater Res.</i> , 2001, 58(1):1-9

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449